Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 13/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | AGXT | P21549 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1715066 | 0.98 | IDO1 (0.61) | IDO1TAAR1SMN1; SMN2AGXTCYP3A4 | |
| SCHEMBL1520774 | 0.85 | TAAR1 (0.60) | IDO1TAAR1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1382024 | 0.83 | TAAR1 (0.58) | IDO1TAAR1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1715797 | 0.83 | TAAR1 (0.58) | IDO1TAAR1SMN1; SMN2 | |
| SCHEMBL865249 | 0.79 | SMN1; SMN2 (0.52) | IDO1TAAR1SMN1; SMN2DPP4 | |
| SCHEMBL19055351 | 0.75 | SMN1; SMN2 (0.48) | IDO1TAAR1SMN1; SMN2DPP4 | |
| SCHEMBL4796828 | 0.75 | SMN1; SMN2 (0.48) | IDO1TAAR1SMN1; SMN2DPP4 | |
| SCHEMBL13108637 | 0.75 | SMN1; SMN2 (0.48) | IDO1TAAR1SMN1; SMN2DPP4 | |
| SCHEMBL4796836 | 0.75 | SMN1; SMN2 (0.48) | IDO1TAAR1SMN1; SMN2DPP4 | |
| SCHEMBL9366433 | 0.73 | IDO1 (1.00) | IDO1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-8119631-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
| EP-2295442-A2 | Inhibitors of interleukin-1beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7790713-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2083014-A2 | Inhibitors of interleukin-1ß converting enzyme | Vertex Pharmceuticals Incorporated (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20080039449-A1 | Inhibitors of interleukin-1beta converting enzyme | BATCHELOR MARK J | 2008-02-14 | — | — | US | disclosed |
| US-20050143436-A1 | Inhibitors of interleukin-1beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED | 2005-06-30 | — | — | US | disclosed |
| US-20030225269-A1 | Inhibitors of interleukin-1beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED | 2003-12-04 | — | — | US | disclosed |
| US-6423840-B1 | FORMING N-ACYLAMINO COMPOUND | VERTEX PHARMACEUTICALS INCORPORATED | 2002-07-23 | — | — | US | disclosed |
| EP-0869967-A2 | INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997022619-A2 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-06-26 | — | — | WO | disclosed |
| EP-0113092-B1 | 1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-4-OXO-7-(4-(OXOALKYL)-1-PIPERAZINYL)-3-QUINOLINE-CARBOXYLIC ACIDS AND THEIR DERIVATIVES, PROCESS FOR THEIR PREPARATION AND ANTIBACTERIAL AGENTS CONTAINING THEM | BAYER AG (DE) | 1986-05-21 | — | — | EP | disclosed |
| US-4547503-A | 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[4-(oxo-alkyl)-1-piperazinyl]quinoline-3-carboxylic acids and their derivatives, and antibacterial agents containing them | BAYER AKTIENGESELLSCHAFT (DE) | 1985-10-15 | — | — | US | disclosed |
| EP-0113092-A1 | 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-(oxoalkyl)-1-piperazinyl)-3-quinoline-carboxylic acids and their derivatives, process for their preparation and antibacterial agents containing them | BAYER AG (DE) | 1984-07-11 | — | — | EP | disclosed |
| EP-0015456-B1 | OMEGA-HALOGENO-ACETOPHENONE OXIME ETHERS, PREPARATION THEREOF AND THEIR USE AS INTERMEDIATES IN THE PREPARATION OF OMEGA-AZOLYL-ACETOPHENONE OXIME ETHERS | BAYER AG (DE) | 1981-12-02 | — | — | EP | disclosed |
| US-4293715-A | FUNGICIDES, BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1981-10-06 | — | — | US | disclosed |
| EP-0002450-B1 | 1-N-SUBSTITUTED-4,6-DI-O-(AMINOGLYCOSYL)-1,3-DIAMINO-CYCLITOL DERIVATIVES, PROCESS FOR PREPARING THEM AND MEDICAMENTS CONTAINING THEM | BAYER AG (DE) | 1981-05-20 | — | — | EP | disclosed |
| US-4234572-A | AMINOGLYCOSIDE ANTIBIOTICS | BAYER AKTIENGESELLSCHAFT (DE) | 1980-11-18 | — | — | US | disclosed |
| EP-0002450-A1 | 1-N-substituted-4,6-di-O-(aminoglycosyl)-1,3-diamino-cyclitol derivatives, process for preparing them and medicaments containing them | BAYER AG (DE) | 1979-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | IDO1 119/4885TAAR1 4821/4885SMN1; SMN2 2804/4885 |
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | IDO1 119/4885TAAR1 4821/4885SMN1; SMN2 2804/4885 |
| US-20080039449-A1 | Inhibitors of interleukin-1beta converting enzyme | IL1A, IL1B, IFNAR1 | IDO1 125/4885TAAR1 4830/4885SMN1; SMN2 2598/4885 |
| US-20050143436-A1 | Inhibitors of interleukin-1beta converting enzyme | IL1A, IL1B, IFNAR1 | IDO1 113/4885TAAR1 4820/4885SMN1; SMN2 2615/4885 |
| US-20030225269-A1 | Inhibitors of interleukin-1beta converting enzyme | IL1A, APAF1, IL1B | IDO1 95/4885TAAR1 4846/4885SMN1; SMN2 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.